Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Hemorrhage 2 Thrombocytopenia 1 Recurrence 1 Postoperative Hemorrhage 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1 Blood Loss, Surgical 1

Interventions

Cyclophosphamide 21 venetoclax 18 pembrolizumab 16 Dexamethasone 16 fludarabine 14 Cytarabine 13 Gemcitabine 9 pomalidomide 8 Rituximab 8 Carboplatin 8 Azacitidine 8 glofitamab 7 fludarabine phosphate 7 Lenalidomide 7 Immunotherapy, Adoptive 7 selinexor 6 Paclitaxel 6 Injections 6 Granulocyte Colony-Stimulating Factor 6 Cisplatin 6 daratumumab 5 Temozolomide 5 Oxaliplatin 5 Bevacizumab 5 zanubrutinib 4 ruxolitinib 4 Surgical Procedures, Operative 4 Nivolumab 4 Drug Therapy 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × Tranexamic Acid × Clear all

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡